NeurologyNew epilepsy pill halved seizures for many hard-to-treat patients
In the phase 3 X-TOLE2 trial, once-daily azetukalner cut monthly focal seizures by a median 53% at the higher dose, against 10% on placebo, in drug-resistant epilepsy.
9 November 2026